The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Mesenchymal stem cells as vehicles for gene delivery.
J D Mosca; J K Hendricks; D Buyaner; J Davis-Sproul; L C Chuang; M K Majumdar; R Chopra; F Barry; M Murphy; M A Thiede; et al. (Profiled Author: Janice Davis Sproul)
Osiris Therapeutics, Inc, Baltimore, MD, USA.
Clinical orthopaedics and related research 2000;(379 Suppl):S71-90.
Mesenchymal stem cells contribute to the regeneration of mesenchymal tissues such as bone, cartilage, muscle, ligament, tendon, adipose, and marrow stroma. Transduction of mesenchymal stem cells from species other than humans is required for the development of disease models in which mesenchymal stem cells-based gene delivery is evaluated. Attempts to transduce mesenchymal stem cells from some species with amphotropic retroviral vectors were unsuccessful, leading to comparative mesenchymal stem cells transductions with xenotropic and gibbon-ape leukemia virus envelope-pseudotyped retroviral vectors. Human, baboon, canine, and rat mesenchymal stem cells were transduced optimally with amphotropic vector supernatants. In contrast, sheep, goat, and pig mesenchymal stem cells showed highest transduction levels with xenotropic retroviral vector supernatant, and rabbit mesenchymal stem cells were transduced optimally with gibbon-ape-enveloped vectors. Using a myeloablative canine transplantation model and gene-marked canine mesenchymal stem cells, the biodistribution of infused and ex vivo expanded mesenchymal stem cells were examined. The majority of transduced canine mesenchymal stem cells were found in the bone marrow samples. The current study shows the use of mesenchymal stem cells as a delivery vehicle for gene transfer studies, and validates the feasibility of delivering mesenchymal stem cells to the marrow compartment for stromal regeneration after cancer-associated cytotoxic therapies.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
K Lee; M K Majumdar; D Buyaner; J K Hendricks; M F Pittenger; J D MoscaMolecular therapy : the journal of the American Society of Gene Therapy 2001;3(6):857-66.
Z Gao; J Golob; V M Tanavde; C I Civin; R G Hawley; L ChengStem cells (Dayton, Ohio) 2001;19(3):247-59.
L Cheng; C Du; D Murray; X Tong; Y A Zhang; B P Chen; R G HawleyGene therapy 1997;4(10):1013-22.
Appears in this Publication
Author of this Publication